Luis E. Aguirre

Luis E. Aguirre

Auto-generated profile, based on publicly available information

Luis E. Aguirre

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2018 in The Oncologist
Verified
Journal Article
Open access
PDF file
LALuis E. Aguirre
Luis E. Aguirre
MGMaria E. Guzman
Maria E. Guzman
GLGilberto Lopes
Gilberto Lopes
JHJudith Hurley
Judith Hurley
Background: It is well known that the state of immune tolerance induced by broad immunosuppression to prevent allograft rejection leads to an increased risk of the development of cancer. One of the most promising new areas of cancer treatment has been the development of immune checkpoint inhibitors that target the cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1/programmed death-ligand 1 (PD-L1) pathways. As a logical consequence, growing interest in these agents translated into their implementation in patients with transplant-related malignancies. Because of overlapping and perhaps mutually exclusive mechanisms of action of transplant immunosuppression and cancer immunomodulation, it is critical to examine these interactions.Materials and Methods: We carried out a systematic search for review articles and case reports published between July 2014 and November 2017 using three engines: Usearch, PubMed, and Up-to-date.Results: Overall, there were 20 cases with 12 allograft rejections. The rejection rate associated with nivolumab was 73% (8/11) and with pembrolizumab it was 100% (2/2). The use of ipilimumab did not lead to rejection in any instance (0/4, 0%). Of the two patients treated with the sequential use of ipilimumab/nivolumab, one lost his allograft, yielding a rejection rate of 50%. The sequential use of ipilimumab/pembrolizumab led to a rejection rate of 100% (1/1, 100%).Conclusion: The use of agents that act on the PD-L1 pathway are contraindicated in the face of solid organ allografts because of unacceptably high rates of irreversible allograft rejection. It appears that the use of ipilimumab may be tolerated as the mechanism is different from that of the PD-L1 agents.Implications for Practice: Transplant rejection is a complex process that puts stress on patients and their families and can lead to tragic results. Significant advancements in the field of immunosuppression have led to the engenderment of agents devised to extend the survival of transplant recipients. The advent of immunomodulators in cancer therapy has been paradigm-shifting; however, because of their mechanism of action, their use must be carefully considered in patients with allografts and concomitant cancer. It appears that ipilimumab can be administered safely in these patients but that agents acting on the programmed death-ligand 1 pathway are contraindicated because of high rates of irreversible rejection.


5 May 2023 in Leukemia
Verified
Journal Article
Closed access
PDF file
LALuis E. Aguirre
Luis E. Aguirre
NANajla Al Ali
Najla Al Ali
DSDavid Sallman
David Sallman
SBSomedeb Ball
Somedeb Ball
AJAkriti G. Jain
Akriti G. Jain
RKRami S. Komrokji
Rami S. Komrokji

17 July 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
RKRami S. Komrokji
Rami S. Komrokji
LALuis E. Aguirre
Luis E. Aguirre
NANajla H. Al Ali
Najla H. Al Ali
OCOnyee Chan
Onyee Chan
ZXZhuoer Xie
Zhuoer Xie
DSDavid Sallman
David Sallman
Rami S. Komrokji, Luis E. Aguirre, Najla Al-Ali, Onyee Chan, Zhuoer Xie, Andrew T. Kuykendall, Kendra L Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman;

12 February 2025 in HemaSphere
Verified
Journal Article
Open access
ACAngela Consagra
Angela Consagra
LLLuca Lanino
Luca Lanino
NANajla H. Al Ali
Najla H. Al Ali
LALuis Aguirre
Luis Aguirre
ZXZhuoer Xie
Zhuoer Xie
RKRami S. Komrokji
Rami S. Komrokji
We explored the impact of luspatercept therapy on overall survival (OS) and possible predictors of response in low‐risk (LR) myelodysplastic syndrome (MDS) patients. We evaluated 331 anemic patients treated with luspatercept. Hematological response (HI) was defined as (i) hemoglobin (Hb) increase of ≥1.5 g/dL in nontransfusion‐dependent (NTD) patients, and (ii) red blood cell (RBC) transfusion independence (TI) with a concomitant Hb increase of ≥1.5 g/dL, or RBC‐TI without an Hb increase of 1.5 g/dL, or >50% reduction in RBC transfusion burden (TB) for TD patients. Response was observed in 166 patients (50.2%), with significantly higher response in NTD and low TB versus high TB patients ( p < 0.001). A significant correlation between lower Molecular International Prognostic Scoring System (IPSS‐M) risk scores and response was observed. No statistically significant difference in HI was found in SF3B1‐ mutated versus wild‐type MDS patients (53.8% vs. 40.1%, respectively). SF3B1 mut hotspots (K700E vs. others) and variant allele frequencies (VAFs; <38% VAF vs. ≥38% VAF) did not impact on HI. SF3B1‐ mutated MDS with del5q showed inferior HI compared to other LR‐MDS ( p = 0.046). The median treatment duration overall was 35 weeks (20.86–90.29), the median time to response was 11 weeks (8.71–21.86), and the median duration of response was 65 weeks (26.5–114). After a median follow‐up of 13 months, median OS was not reached (NR) for responders and 24 months for nonresponders (hazard ratio [HR] 0.25, 95% confidence interval 0.14–0.44, p  < 0.001). This analysis of 331 luspatercept real‐life‐treated LR‐MDS patients demonstrated a significant OS benefit upon luspatercept response. Low baseline RBC‐TB and lower risk IPSS‐M scores correlated with higher HI and could constitute predictive markers of response.

28 September 2018 in Cureus
Verified
Journal Article
Open access
PDF file
IEIbeth S. Erazo
Ibeth S. Erazo
CGClaudio F. Galvis
Claudio F. Galvis
LALuis E Aguirre
Luis E Aguirre
RIRoman Iglesias
Roman Iglesias
LALuz C. Abarca
Luz C. Abarca
Chordomas are rare, slow-growing, and locally aggressive malignant neoplasms derived from primitive notochord remnants. The chondroid variety represents 14% of all chordomas mainly developing in the spheno-occipital region and presenting between the third and fifth decades of life. When developing intracranially, symptoms can range from headaches and neck pain to cranial nerve neuropathies and facial numbness. We illustrate a case of an adolescent woman who presented with excruciating facial pain, otalgia, decreased visual acuity, quadriparesis, headache, nausea, and dysphagia. Radiological studies revealed a large heterogeneous mass in the spheno-occipital region with clivus destruction. Biopsy and histopathology confirmed the diagnosis. Proper identification with prompt surgical resection and adjuvant radiotherapy remains critical to prevent complications.